FDA, Federal Trade Commission to target ‘anti-competitive’ practices to support biosimilars

The FDA and the Federal Trade Commission on Monday announced a partnership aimed at supporting the adoption of biosimilars and interchangeable products by deterring what they called “anti-competitive business practices,” such as false or misleading promotions, according to a joint statement.“Competition is key for helping American patients have access to affordable medicines,” FDA Commissioner Stephen M. Hahn, MD, said in the statement. “While these therapies are critical for patients, biological products contribute significantly to drug costs, as they are oftenRead More